Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Read more about Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Read more about Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases
Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Read more about Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
Xencor's Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology Read more about Xencor's Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology
Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Read more about Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies Read more about Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration Read more about Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration
MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL - Study Data Expected in Q4 2012 Read more about MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL - Study Data Expected in Q4 2012
MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574 - Phase 1/2a Trial in CLL/SLL Patients Met Primary and Secondary Objectives Read more about MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574 - Phase 1/2a Trial in CLL/SLL Patients Met Primary and Secondary Objectives
Xencor Receives Milestone Payment for Xtend™ Antibody Read more about Xencor Receives Milestone Payment for Xtend™ Antibody
